Patrick McGrady
Overview
Explore the profile of Patrick McGrady including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
829
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang L, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, et al.
Cancer
. 2013 Aug;
119(20):3718-26.
PMID: 23901000
Background: This study sought to investigate biological/clinicopathological characteristics of neuroblastoma, undifferentiated subtype (NBUD). Methods: This study examined 157 NBUD cases filed at the Children's Oncology Group Neuroblastoma Pathology Reference Laboratory,...
2.
Yanik G, Parisi M, Shulkin B, Naranjo A, Kreissman S, London W, et al.
J Nucl Med
. 2013 Feb;
54(4):541-8.
PMID: 23440556
Unlabelled: Radiolabeled metaiodobenzylguanidine (mIBG) is a highly sensitive and specific marker for detecting neuroblastoma. A semiquantitative mIBG score (Curie score [CS]) was assessed for utility as a prognostic indicator for...
3.
Villablanca J, London W, Naranjo A, McGrady P, Ames M, Reid J, et al.
Clin Cancer Res
. 2011 Sep;
17(21):6858-66.
PMID: 21908574
Purpose: To determine the response rate to oral capsular fenretinide in children with recurrent or biopsy proven refractory high-risk neuroblastoma. Experimental Design: Patients received 7 days of fenretinide: 2,475 mg/m(2)/d...
4.
Henderson T, Bhatia S, Pinto N, London W, McGrady P, Crotty C, et al.
J Clin Oncol
. 2010 Nov;
29(1):76-82.
PMID: 21098321
Purpose: Although health disparities are well-described for many cancers, little is known about racial and ethnic disparities in neuroblastoma. To evaluate differences in disease presentation and survival by race and...
5.
6.
Lagmay J, London W, Gross T, Termuhlen A, Sullivan N, Axel A, et al.
Clin Cancer Res
. 2009 Aug;
15(16):5234-9.
PMID: 19671870
Purpose: Neuroblastoma is a childhood cancer of the sympathetic nervous system and many patients present with high-risk disease. Risk stratification, based on pathology and tumor-derived biomarkers, has improved prediction of...
7.
Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, et al.
Lancet Oncol
. 2009 Jun;
10(7):663-71.
PMID: 19515614
Background: More accurate prognostic assessment of patients with neuroblastoma is required to better inform the choice of risk-related therapy. The aim of this study is to develop and validate a...
8.
Combaret V, Hogarty M, London W, McGrady P, Iacono I, Brejon S, et al.
Pediatr Blood Cancer
. 2009 Mar;
53(3):329-31.
PMID: 19301388
Background: MYCN oncogene amplification has been defined as the most important prognostic factor for neuroblastoma (NB), the most common solid extracranial neoplasm in children. High copy numbers are strongly associated...
9.
George R, Sanda T, Hanna M, Frohling S, Luther 2nd W, Zhang J, et al.
Nature
. 2008 Oct;
455(7215):975-8.
PMID: 18923525
Neuroblastoma, an embryonal tumour of the peripheral sympathetic nervous system, accounts for approximately 15% of all deaths due to childhood cancer. High-risk neuroblastomas are rapidly progressive; even with intensive myeloablative...
10.
Beierle E, Massoll N, Hartwich J, Kurenova E, Golubovskaya V, Cance W, et al.
Clin Cancer Res
. 2008 Jun;
14(11):3299-305.
PMID: 18519756
Purpose: The focal adhesion kinase (FAK) is a nonreceptor protein tyrosine kinase important in signaling between cells and their extracellular matrix. Studies have shown that FAK expression is up-regulated in...